{
    "2021-02-05": [
        [
            {
                "time": "",
                "original_text": "比药明康德还猛！8年40倍，盈利无敌的临床CRO龙头",
                "features": {
                    "keywords": [
                        "药明康德",
                        "临床CRO",
                        "盈利"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【异动股】泰格医药(03347-HK)跌3.05%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "下跌"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "高瓴资本概念股表现活跃，海正药业封板、健帆生物一度涨停",
                "features": {
                    "keywords": [
                        "高瓴资本",
                        "海正药业",
                        "健帆生物",
                        "涨停"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中信证券：第四批带量采购降价符合预期 未来带量采购对市场冲击料将减小",
                "features": {
                    "keywords": [
                        "中信证券",
                        "带量采购",
                        "降价",
                        "市场冲击"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}